Lung fibrosis in systemic sclerosis treated with a combination of ciclosporin and azathioprine [8]

Clinical and Experimental Rheumatology

Volumn 24, Issue 2, 2006, Pages 215-

  Hider, S L ^a   Woodhead, M ^b   Taylor, P M ^b   Bruce, Ian N ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; PREDNISOLONE;

ADULT; CASE REPORT; DIAGNOSTIC IMAGING; DISEASE DURATION; DRUG MEGADOSE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LABORATORY TEST; LETTER; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG TRANSFER FACTOR; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; TREATMENT REFUSAL;

ADULT; AZATHIOPRINE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SODIUM PERTECHNETATE TC 99M; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33744820000     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (12)

1. WHITE B: Interstitial brag disease in scleroderma. Rheum Dis Clin North Am 2003; 29: 371-90.
2. HARRISON NK, GLANVILLE AR, STRICKLAND B et al.: Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir Med 1989; 83: 403-14.
3. KON OM, DANIIL Z, BLACK CM, DU BOIS RM: Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis. European Respiratory Journal 1999; 13: 133-6.
4. WHITE B, MOORE WC, WIGLEY FM, XIAO HQ, WISE RA: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-54.
5. GIACOMELLI R, VALENTINI G, SALSANO F et al.: Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29: 731-6.
6. PAKAS I, IOANNIDIS JP, MALAGARI K, SKOPOULI FN, MOUTSOPOULOS HM, VLACHOYIANNOPOULOS PG: Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. Journal of Rheumatology 2002; 29: 298-304.
7. SCHNABEL A, REUTER M, GROSS WL: Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998; 41: 1215-20.
8. STEEN VD, LANZ JK, JR, CONTE C, OWENS GR, MEDSGER TA, JR: Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994; 37: 1290-6.
9. NICOD LP: Recognition and treatment of idiopathic pulmonary fibrosis. Drugs 1998; 55: 555-62.
10. Dheda K, Lalloo UG, Cassim B, Mody GM: Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004; 23: 306-9.
11. SAUTY A, ROCHAT T, SCHOCH OD et al.: Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J 1997; 10: 2907-12.
12. FILACI G, CUTOLO M, BASSO M et al.: Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology 2001; 40: 1431-2.